- 22 Oct 2020 – Alligator Bioscience AB (publ): Interim report January-September 2020
- 22 Oct 2020 – Alligator Bioscience focuses on ATOR-1017 and mitazalimab
- 28 Sep 2020 – Alligator Bioscience appoints Gayle Mills as Chief Business Officer
- 24 Sep 2020 – Alligator Bioscience launches a new immuno-oncology concept
Alligator Bioscience Virtual R&D Day - Aug 27
Alligator held a virtual R&D Day on August 27, in which CEO Per Norlén and COO Malin Carlsson gave an update on the status and latest development steps in the company's clinical pipeline. Guest speaker, Professor Ignacio Melero at University of Navarra, gave his view on 4-1BB, the target for ATOR-1017. Listen to the presentations here.